Search clinical trials for: Crisaborole Placebo Vehicle

Total 54679 results

Pfizer

Completed

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China, Japan, Korea, Republic of
Pfizer

Completed

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

China, United States, Turkey, Australia, Canada, Israel
Pfizer

Completed

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Healthy | Atopic Dermatitis

Japan
Pfizer

Completed

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
Pfizer

Completed

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Stasis Dermatitis

United States
Pfizer

Completed

Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Dermatitis, Atopic

Canada
Boston University
Pfizer

Terminated

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PAD)

Atopic Dermatitis

United States
Innovaderm Research Inc.

Completed

Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis

Dermatitis, Atopic

Canada
Tufts Medical Center
Pfizer

Withdrawn

Topical Crisaborole in Patients With Alopecia Areata

Alopecia Areata

United States
Pfizer

Terminated

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
Northwestern University
Pfizer

Completed

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Atopic Dermatitis

United States
University of Colorado, Denver
Pfizer

Active, not recruiting

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

Vitiligo

United States
Pfizer

Completed

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Canada
University of California, Irvine
Pfizer

Completed

Characterizing Skin Microbiome Change in Atopic Dermatitis

Atopic Dermatitis | Atopic Dermatitis Eczema

United States
Duke University
Pfizer

Completed

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Morphea

United States
Intravacc B.V.
Novotech (Australia) Pty Limited

Completed

Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers (ITV2002)

COVID-19

Australia
Ann & Robert H Lurie Children's Hospital of Chicago
Pfizer

Completed

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Eczema | Atopic Dermatitis

United States
University of Alabama at Birmingham

Completed

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Seborrheic Dermatitis

United States
Massachusetts General Hospital
Pfizer

Active, not recruiting

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Galderma R&D

Completed

Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis

Psoriasis

Taiwan
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Taro Pharmaceuticals USA

Completed

A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study

Plaque Psoriasis
Raziel Therapeutics Ltd.

Completed

RZL-012 for Dercum's Disease Lipomas

Dercum's Disease Lipomas

United States
Trefoil Therapeutics, Inc.

Completed

A Phase 1/ Phase 2 Study of TTHX1114(NM141) (INTREPID)

Endothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal Dystrophy

United States
Celularity Incorporated
Celgene Corporation

Terminated

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
New York Medical College
U.S. Army Medical Research and Development Command; Westchester Medical Center

Unknown

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

Stress Disorders, Post-Traumatic | Stress Disorders, Traumatic, Acute

United States
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Integra LifeSciences Corporation
Integrium

Terminated

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers (STRIDE 1)

Diabetic Foot Ulcers

United States
Taro Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

Onychomycosis

United States
Incyte Corporation

Active, not recruiting

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Atopic Dermatitis

United States, Canada
Bayer

Completed

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

Atopic Dermatitis

South Africa
Taro Pharmaceuticals USA

Completed

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis
Novan, Inc.
Novella Clinical

Completed

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

Psoriasis

United States
Sophiris Bio Corp

Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH (PLUS-1)

Benign Prostatic Hyperplasia

United States, Australia, Canada, Russian Federation, Ukraine, New Zealand
Amber Ophthalmics, Inc.

Recruiting

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED (NEXPEDE-1)

Persistent Corneal Epithelial Defect

United States
Hapten Sciences, Inc.
Milton S. Hershey Medical Center

Not yet recruiting

A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB

Contact Dermatitis
Helixmith Co., Ltd.

Terminated

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

Foot Ulcer, Diabetic

United States
Microbion Corporation

Completed

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

Diabetic Foot Infection

United States
Sun Yat-sen University

Recruiting

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (COSTIC)

Metastatic Colorectal Cancer | Cetuximab | Skin Toxicity

China
Allergan

Terminated

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

United States, Austria, Poland, Germany
PellePharm, Inc.

Completed

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas (BCC)

Basal Cell Carcinomas

United States
Taro Pharmaceuticals USA

Completed

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis

United States
Peplin

Completed

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Atopic Dermatitis

China
BiomX, Inc.

Active, not recruiting

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Cystic Fibrosis | Chronic Pseudomonas Aeruginosa Infection

United States, Israel, Spain, Czechia, Netherlands
Novan, Inc.
Chiltern International Inc.

Completed

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne

Acne Vulgaris

United States
Medicis Global Service Corporation

Completed

Safety and Efficacy Study to Treat Bacterial Vaginosis

Bacterial Vaginosis

United States
Novan, Inc.
Chiltern International Inc.

Completed

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

Acne Vulgaris

United States
PRG Science & Technology Co., Ltd.
Amarex Clinical Research

Completed

Phase I Study of Progerinin in Healthy Volunteers

Hutchinson-Gilford Progeria Syndrome | Werner Syndrome

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

Tinea Pedis

United States

3

Subscribe